26
|
Cramer E, Rieß FC, Wahl G, Kremer P. The Medtronic mosaic prosthesis: Clinical perfomance up to 16 years. Thorac Cardiovasc Surg 2011. [DOI: 10.1055/s-0030-1268969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
|
28
|
Rieß FC, Cramer E, Wahl G, Bader R, Hansen L. The medtronic mosaic prosthesis: clinical performance at 15 years. Thorac Cardiovasc Surg 2010. [DOI: 10.1055/s-0029-1246719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Cramer E, Herle K, Balakrishnan N. Permanent Expansions and Distributions of Order Statistics in the INID Case. COMMUN STAT-THEOR M 2009. [DOI: 10.1080/03610920802311725] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Fischer T, Balakrishnan N, Cramer E. Mixture representation for order statistics from INID progressive censoring and its applications. J MULTIVARIATE ANAL 2008. [DOI: 10.1016/j.jmva.2008.02.007] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Cramer E, Bader R, Wahl G, Matthies M, Rieß FC. The Medtronic MOSAIC prosthesis: clinical performance at 13 years. Thorac Cardiovasc Surg 2008. [DOI: 10.1055/s-2008-1037703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Riess FC, Poetzsch B, Madlener K, Cramer E, Doll KN, Doll S, Lorke DE, Kormann J, Mueller-Berghaus G. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. Thorac Cardiovasc Surg 2007; 55:233-8. [PMID: 17546553 DOI: 10.1055/s-2006-955956] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND Lepirudin, a recombinant hirudin, is a direct acting thrombin inhibitor that has been used as a heparin alternative in patients with heparin-induced thrombocytopenia requiring on-pump cardiac surgery. To evaluate the efficacy, safety, and clinical utility of lepirudin as a cardiopulmonary bypass (CPB) anticoagulant, we compared lepirudin with heparin in a routine CPB setting. METHODS Twenty patients were randomly assigned to receive lepirudin (0.25 mg/kg b. w. bolus and 0.2 mg/kg b. w. added to the CPB priming) or heparin (400 U/kg b. w. bolus) with protamine reversal. Lepirudin and heparin anticoagulation during CPB was monitored using the ecarin clotting time or ACT, respectively and additional lepirudin (5 mg) or heparin (5000 U) boluses were administered. RESULTS The CPB circuit was performed in both groups without thromboembolic complications. Median blood loss during the first 36 hours was statistically higher ( P = 0.007) in the lepirudin group (1.226 +/- 316 ml) compared to the heparin group (869 +/- 189 ml). One patient of the lepirudin group developed pulmonary embolism 24 hours after surgery. This patient was tested homozygous for the FV-Leiden mutation. CONCLUSION Lepirudin provides effective CPB anticoagulation but induces a higher postoperative blood loss than heparin. Lepirudin should be restricted to patients undergoing CPB who cannot be exposed to heparin.
Collapse
|
33
|
Burkschat M, Cramer E, Kamps U. Optimality Criteria and Optimal Schemes in Progressive Censoring. COMMUN STAT-THEOR M 2007. [DOI: 10.1080/03610920601077196] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Kurbacher CM, Kurbacher JA, Cramer E, Reinhold U, Nagel WJ, Reichelt R, Cree IA. A phase II study of low-dose prolonged infusional gemcitabine combined with oral treosulfan in patients with platinum- and taxane-resistant ovarian cancer or other Mullerian tract carcinomas. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.15004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15004 The prognosis of patients (pts) with epthelial ovarian cancer (EOC) and other Mullerian tract carcinomas such as papillary-serous peritoneal carcinoma (PSPC), fallopian tube cancer (FTC), and uterine papillary-serous carcinoma (UPSC) resistant to both platinum and taxanes is particularly poor. Recently, we have reported preliminary results of modified GeT - gemcitabine (dFdC) and treosulfan (TREO) (Kurbacher et al, Proc ASCO 2005). Now, mature results of this phase II trial are available. A total of 35 patients (pts) were included (EOC, 29; FTC, 4; PSPC, 1; UPSC, 1). Patients had failed a median of 2 prior chemotherapies (1, n = 10; 2, n = 11; 3, n = 7; 4, n = 3; 5, n = 3; 7, n = 1) including platinum and paclitaxel in all, anthracyclines in 16, dFdC in either 6, and topotecan in 5 pts. GeT was administered at a q2w schedule with dFdC at 450 mg/m2 (3 h infusion), day 1, and oral TREO at 1,000 mg/m2/d, day 1–4. A total of 192 cycles were given with a median of 6 (range: 2–10). All pts had measurable or evaluable disease according to RECIST and Rustin criteria, repectively. All treatments were evaluable for both toxicity and response. Myelosuppression was frequent but exceeded NCI-CTC grade 2 in only 17/192 cycles (9%). G 3–4 neutropenia was observed during 5/192 cycles (3%), G 3–4 thrombocytopenia did not occur. Interval prolongation due to febrile urinary tract infection or subileus was necessary in two pts. In another patient, treatment was terminated due to non-fatal pulmonary embolism. Other toxicities did not exceed NCI-CTC grade 2 nor did any other patient require hospitalization due to therapy-related complications. A total of 11 CR, 7 PR, 9 SD, and 8 PD were recorded accounting for an objective response rate of 51% with 27 pts (77%) benefiting from GeT. The median progression-free survival was 27 weeks. Until now, 15 pts are still alive, the median overall survival is 76.5 weeks. Regarding the intensive pre-treatment of the pts, the modified GeT treatment was easy to tolerate and produced a promising clinical efficacy in EOC and other Mullerian tract carcinomas resistant to both platinum and taxanes. Large-scaled clinical trials are now warrented to confirm these encouraging results. No significant financial relationships to disclose.
Collapse
|
35
|
Cramer E, Moers C, Zarghooni V, Bosse K, Mallmann P, Warm M. Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin (E) and cyclophosphamide (C) followed by docetaxel (T) in primary breast cancer (BC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10656 Background: Primary chemotherapy is established in the treatment of local advanced BC. Two important advances are the chance to detect the clinical responders during the chemotherapy and an increasing rate of breast conserving surgery (BCS). According to the promissing results of dose-dense chemotherapy schedules in the adjuvant setting we tested the benefit of this approach in a primary chemotherapy protocol. Methods: This clinical trial (01/2003–11/2005) enrolled 93 females with advanced (cT2-cT4), non metastatic BC. The pts received four courses of E (90 mg/m2) and C (600 mg/m2) q2w, followed by four courses of T (100/75 mg/m2) q2w. The severe hand-foot-skin reaction NCI-CTG grade 3 during the T courses of the first pts (G1: n = 19) lead to a dose reduction of T to 75 mg/m2 for the following pts (G2: n = 73). During the first four cycles Pegfilgrastim was applied to prevent neutropenic complications. After every two cycles the actual tumor size was measured by clinical and sonographical examination. The clinical and pathological response, the toxicity and the rate of BCS were evaluated. Results: Pathological complete remission (pCR) of the invasive tumors was observed in 7/19 pts (G1) and 17/73 (G2), pathological partial remission (pPR) in 7/19 pts (G1) and 28/73 (G2), minimal response (pMR) in 3/19 pts (G1) and 14/73 (G2), a stable disease in 2/19 pts (G1) and 11/73 (G2). Two pts in group two showed a progressive disease (pPD). Three pts developed neutropenic fever and stopped the chemotherapy after the 5th and 6th cycle, respectively. One patient died after the 8th cycle in neutropenic sepsis. During this trial the main side effect of T was a hand-foot-skin reaction. Conclusions: This neoadjuvant dose-dense chemotherapy is a potent schedule for the treatment of primary BC. Using T with 75 mg/m2 instead of 100 g/m2 is generally better tolerated. The first group of pts treated with T 100 mg/m2 exhibited a higher frequency of pCR (36.8%) compared to the pts treated with 75 mg/m2 (pCR 23.3%), (p = 0.23). But the increased rate of severe side effects lead to an early dose reduction to 75 mg/m2 in this clinical trial.These first promissing results will be improved in an enlarged number of pts. No significant financial relationships to disclose.
Collapse
|
36
|
|
37
|
Riess FC, Bader R, Cramer E, Hansen L, Wahl G, Winkel S, Bleese N. Hemodynamic performance and clinical follow-up of the medtronic mosaic bioprosthesis: 10 years experience. Thorac Cardiovasc Surg 2006. [DOI: 10.1055/s-2006-925699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
38
|
Balakrishnan N, Cramer E, Kamps U. Relation for joint densities of progressively censored order statistics. STATISTICS-ABINGDON 2005. [DOI: 10.1080/02331880500366050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Starke R, Harrison P, Mackie I, Wang G, Erusalimsky JD, Gale R, Massé JM, Cramer E, Pizzey A, Biggerstaff J, Machin S. The expression of prion protein (PrP(C)) in the megakaryocyte lineage. J Thromb Haemost 2005; 3:1266-73. [PMID: 15946217 DOI: 10.1111/j.1538-7836.2005.01343.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Cellular prion protein (PrP(C)) is a naturally occurring protein in normal individuals which adopts an abnormal conformation, termed scrapie prion protein (PrP(Sc)) that is associated with disease. There is great concern that clinically asymptomatic variant Creutzfeldt-Jacob disease (vCJD) may transmit PrP(Sc) in blood transfusion products. PrP(C) is widely expressed and has been found in human blood. The majority of cellular borne PrP(C) is associated with platelets (84%). Although PrP(C) mRNA has been demonstrated in platelets, the quantity is unknown and may not reflect the total PrP(C) present. OBJECTIVE To investigate the expression of PrP(C) in the megakaryocyte lineage. METHODS The expression of PrP(C) was studied in CD34+ cells, cultured megakaryocytes and platelets using electron microscopy, flow cytometry, semi-quantitative RT-PCR and immunofluorescence confocal microscopy. RESULTS AND CONCLUSIONS The expression of PrP(C) appeared to increase with differentiation and polyploidization in the megakaryocyte lineage. PrP(C) was located within platelet alpha-granules and its source is likely to be from megakaryocyte precursors. If PrP(Sc) has a similar distribution, these results have implications for the selection of blood donors and preparation of cell-depleted blood products.
Collapse
|
40
|
Winkel S, Bader R, Matthies M, Cramer E, Wahl G, Riess FC, Bleese N. The Medtronic MOSAIC bioprosthesis: Clinical performance at 9 years. Thorac Cardiovasc Surg 2004. [DOI: 10.1055/s-2004-816599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Cramer E, Kamps U, Keseling C. Characterizations via Linear Regression of Ordered Random Variables: A Unifying Approach. COMMUN STAT-THEOR M 2004. [DOI: 10.1081/sta-200038832] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Bardin N, Anfosso F, Massé JM, Cramer E, Sabatier F, Le Bivic A, Sampol J, Dignat-George F. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98:3677-84. [PMID: 11739172 DOI: 10.1182/blood.v98.13.3677] [Citation(s) in RCA: 219] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CD146 is a cell-surface molecule belonging to the immunoglobulin superfamily and expressed in all types of human endothelial cells. Confocal and electron microscopic analysis of confluent human umbilical vein endothelial cells (HUVECs) were used to demonstrate that CD146 is a component of the endothelial junction. Double immunolabeling with vascular endothelial cadherin showed that CD146 is localized outside the adherens junction. Moreover, CD146 expression is not restricted to the junction, since part of the labeling was detectable at the apical side of the HUVECs. Interestingly, cell-surface expression of CD146 increased when HUVECs reached confluence. In addition, the paracellular permeability of CD146-transfected fibroblast cells was decreased compared with that of control cells. Finally, CD146 colocalized with actin, was partly resistant to Triton X-100 extraction, and had its expression altered by actin-disrupting agents, indicating that CD146 is associated with the actin cytoskeleton. These results show the regulated expression of CD146 at areas of cell-cell junction and strongly suggest involvement of CD146 as a mediator of cell-cell interaction.
Collapse
|
43
|
Balakrishnan N, Cramer E, Kamps U. Bounds for means and variances of progressive type II censored order statistics. Stat Probab Lett 2001. [DOI: 10.1016/s0167-7152(01)00104-3] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Vitrat N, Cohen-Solal K, Norol F, Guichard J, Cramer E, Vainchenker W, Wendling F, Debili N. Compared effects of Mpl ligand and other cytokines on human MK differentiation. Stem Cells 2001; 16 Suppl 2:37-51. [PMID: 11012176 DOI: 10.1002/stem.5530160707] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The discovery of the Mpl ligand (Mpl-L), also called thrombopoietin (TPO), has facilitated in vitro investigation of human megakaryocytopoiesis. By confocal microscopy, endomitosis appeared as abortive mitosis skipping late stages of mitosis. No telophase and cytokinesis were observed. A spherical multipolar spindle which limits chromatid segregation was observed. The nuclear envelope subsequently reformed isolating all chromatids in a single nucleus. Platelet shedding was ultrastructurally studied. Platelet release occurred after formation of long cytoplasmic extensions (proplatelet formation), constriction areas delineating platelet territories. Heterogeneity in platelet size may be determined by the length of these extensions. Pegylated-recombinant human megakaryocyte growth and development factor, a truncated form of Mpl-L, was the most efficient cytokine to produce proplatelet-bearing megakaryocytes (MKs) and platelets in vitro. However, functional platelets with a normal ultrastructure could be produced in the presence of a combination of other cytokines. Finally, we investigated whether the induction of MK differentiation by the MS-5 stromal cell lines is due to Mpl-L. MS-5 cells synthesized Mpl-L transcripts and a biologically active protein. When human CD34+ cells were grown in contact or noncontact cultures with MS-5 cells, MK differentiation was observed. Soluble Mpl receptor (sMpl-Fc) addition inhibited MK growth, suggesting that the MK-promoting activity was due to Mpl-L production. Marrow stromal cell lines derived from TPO-/- mice were also able to sustain MK growth. Despite the absence of any production of Mpl-L, the sMpl-Fc continued to inhibit MK differentiation. This result suggests that the sMpl has a direct inhibitory effect and may explain the divergent results in the literature concerning the precise role of Mpl-L on the MK terminal differentiation.
Collapse
|
45
|
Balakrishnan N, Cramer E, Kamps U, Schenk N. Progressive type II censored order statistics from exponential distributions. STATISTICS-ABINGDON 2001. [DOI: 10.1080/02331880108802753] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Starke R, Cramer E, Harrison P. Expression of cell-associated prion protein on normal human platelets. Br J Haematol 2000; 110:748-50. [PMID: 10997993 DOI: 10.1046/j.1365-2141.2000.02239-5.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
47
|
Zermati Y, Fichelson S, Valensi F, Freyssinier JM, Rouyer-Fessard P, Cramer E, Guichard J, Varet B, Hermine O. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol 2000; 28:885-94. [PMID: 10989189 DOI: 10.1016/s0301-472x(00)00488-4] [Citation(s) in RCA: 117] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Erythropoiesis is positively regulated by stem cell factor, interleukin 3, and erythropoietin, which synergize to allow the production of hemoglobinized red blood cells from erythroid progenitors. In contrast, interferon gamma, tumor necrosis factor alpha, and transforming growth factor B(1), (TGF-beta(1)) are powerful inhibitors of erythropoiesis. Interferon gamma and alpha act principally by inducing apoptosis. The aim of this study was to elucidate the mechanisms by which TGF-beta(1) inhibits erythropoiesis. We used an in vitro serum-free system of human red blood cell production. From a virtually pure population of CD36(+) erythroid progenitors, stem cell factor, interleukin 3, and erythropoietin allowed massive proliferation (x300) and promoted terminal red blood cell differentiation. We show here that TGF-beta(1) (2 ng/mL) inhibited the growth of CD36(+) cells by 15-fold. TGF-beta(1) markedly accelerated and increased erythroid differentiation as assessed by hemoglobin and glycophorin expression. Furthermore, May-Grünwald-Giemsa staining and ultrastructural analysis revealed that TGF-beta(1) induced full differentiation toward normal enucleated red cells even in the absence of macrophages. This acceleration of erythroid differentiation did not modify the pattern of hemoglobin chains expression from adult or fetal erythroid progenitors. Analysis of apoptosis, cell cycle and Ki-67 expression showed that TGF-beta(1) inhibited cell proliferation by decreasing the cycle of immature erythroid cells and accelerating maturation toward orthochromatic normoblasts that are not in cycle. We showed that TGF-beta(1) is a paradoxical inhibitor of erythropoiesis that acts by blocking proliferation and accelerating differentiation of erythroid progenitors.
Collapse
|
48
|
Mouly S, Youssefian T, Souni F, Cramer E, Lefrere F, Varet B, Hermine O. Acquired delta-storage pool deficiency associated with idiopathic myelofibrosis. Leuk Lymphoma 2000; 37:623-7. [PMID: 11042524 DOI: 10.3109/10428190009058516] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
A 73-year-old woman complained of easy bruising, as a consequence of prolonged bleeding time despite normal platelet counts. Platelet aggregation profile, mepacrine fluorescence test, flow cytometry and transmission electron microscopy studies led to the diagnosis of delta-storage pool deficiency (SPD) A few months later, she developed hyperleucocytosis with immature granulocytes and erythroblasts. The presence of bone marrow fibrosis and clonal cytogenetic abnormalities led to the diagnosis of idiopathic myelofibrosis (IM). Association between SPD and IM has never been reported. The pathogenesis of this unusual association remains unclear and may involve proliferation of abnormal monoclonal stem cells with differentiation into activated megakaryocytes associated with impaired dense granule development and increased cytokines release which may be. involved in myelofibrosis.
Collapse
|
49
|
Cramer E. Une étoile est née (en direct !) : la plaquette de culture. Med Sci (Paris) 2000. [DOI: 10.4267/10608/1718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Bader-Meunier B, Miélot F, Breton-Gorius J, Cramer E, Guichard J, Landrieu P, Dommergues JP, Tchernia G. Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears. Pediatr Res 1999; 46:158-62. [PMID: 10447108 DOI: 10.1203/00006450-199908000-00005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We retrospectively analyzed the bone marrow (BM) smears of 10 children with mitochondrial cytopathies. Light microscopic examination showed large and coalescent cytoplasmic vacuolization of some BM precursors in nine cases, including two children with normal peripheral blood counts and four with sideroblastic anemia. BM ultrastructural study showed abnormal mitochondria in the erythroid lineage in all three children studied. Ultrastructural studies in two cases revealed a population of giant mitochondria with abnormal ultrastructure coexisting with a population of normal mitochondria in proerythroblasts, basophil erythroblasts, and less commonly in more mature erythroblasts. In a third child, mitochondria were normal in size with cristae either absent or exhibiting abnormal longitudinal orientation. Heteroplasmic segregation of mitochondria during cell division could account for the finding of a double population of cells on ultrastructural examination. These features suggest that cytologic and ultrastructural BM examination could be useful for the diagnosis of mitochondrial disorders. That is, when large and coalescent cytoplasmic vacuoles of BM precursor cells are present, the clinician should search for mitochondrial cytopathy in a child with unexplained cytopenia(s).
Collapse
|